AIFA publishes technical-scientific report on Carvykti for multiple myeloma

The Italian Medicines Agency has published a technical-scientific report dedicated to Carvykti, the commercial name of ciltacabtagene autoleucel, a CAR-T cell-based medicine indicated for adult patients with relapsed and refractory multiple myeloma, that is, a form of the disease that has returned after previous treatments or has not responded to them.

The document, according to reports, brings together in a single text the regulatory information concerning the drug, the clinical and safety data collected during the authorization process, and a cost-effectiveness assessment. This is material intended for professional use — specialist physicians, hospital pharmacists, healthcare decision-makers — rather than for the general public, and the publication falls within the ordinary activities through which AIFA accompanies the introduction of complex and high-cost therapies into the healthcare system.

CAR-T therapies, the category to which Carvykti belongs, involve the genetic modification of the patient’s immune cells to make them capable of recognizing and attacking cancer cells; they are personalized treatments, administered at specialized centers, and their use is normally reserved for cases in which other lines of therapy have not worked. AIFA’s report does not introduce a new authorization, but systematizes existing documentation to support its evaluation in clinical practice.

It should be noted that the news currently comes from a single source (Torrinomedica, which picked up AIFA’s publication); it was not possible to obtain independent confirmation of the document’s publication by the time this edition went to press.

The report does not contain, as such, new trial results: it gathers and organizes clinical and regulatory data already produced during the drug’s authorization process, for use by those who must assess its application in individual clinical cases.